Emend IV止敏吐I.V.

Emend IV

fosaprepitant

Manufacturer:

MSD

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Fosaprepitant dimeglumine
Indications/Uses
Prevention of acute & delayed nausea & vomiting associated w/ highly emetogenic cisplatin-based cancer chemotherapy. Prevention of nausea & vomiting associated w/ moderately emetogenic cancer chemotherapy.
Dosage/Direction for Use
Adult Initiate approx 30 min prior to chemotherapy. Highly emetogenic chemotherapy regimen 150 mg IV infusion over 20-30 min on day 1, in conjunction w/ dexamethasone & standard dose of 5-HT3 antagonist. Dexamethasone on day 1: 12 mg orally; day 2: 8 mg orally in the morning; days 3-4: 8 mg orally bd (morning & evening). Moderately emetogenic chemotherapy regimen 150 mg IV infusion over 20-30 min on day 1, in conjunction w/ dexamethasone 12 mg orally & standard dose of 5-HT3 antagonist.
Contraindications
Hypersensitivity to fosaprepitant dimeglumine, polysorbate 80 or any other excipients. Co-administration w/ pimozide, terfenadine, astemizole, cisapride.
Special Precautions
Use w/ caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 & w/ a narrow therapeutic range eg, cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, & quinidine. Concomitant administration w/ irinotecan might result in increased toxicity. In patients on chronic warfarin therapy, closely monitor INR for 14 days following the use of fosaprepitant. Potential reduced effect of hormonal contraceptives. Hypersensitivity reactions. Infusion site reactions. Should not be given as bolus inj, IM or SC. Patients w/ moderate to severe hepatic impairment. Minor influence on the ability to drive & use machines. Pregnancy & lactation.
Adverse Reactions
Hiccups, increased ALT, dyspepsia, constipation, headache, decreased appetite, fatigue.
Drug Interactions
Transient increase in plasma conc of drugs metabolised through CYP3A4 eg, cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, quinidine. Increased AUC of dexamethasone. Transient moderate increase followed by mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (eg, cyclosporine, tacrolimus, everolimus, sirolimus). Potential increased plasma conc of midazolam or other benzodiazepines metabolised via CYP3A4 eg, alprazolam, triazolam. Potential small decrease in BP w/ diltiazem. Caution when co-administered w/ warfarin, acenocoumarol, tolbutamide, phenytoin & other drugs metabolised by CYP2C9. Efficacy of hormonal contraceptives may be reduced. Increased plasma conc of aprepitant w/ CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, PIs). Reduced plasma conc of aprepitant w/ strong CYP3A4 inducers (eg, rifampicin, phenytoin, carbamazepine, phenobarb); St. John's Wort.
ATC Classification
A04AD12 - aprepitant ; Belongs to the class of other antiemetics.
Presentation/Packing
Form
Emend IV powd for infusion 150 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in